10-K: Greenland Mines Pivots to Mining Amidst Mounting Losses

Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., is shifting its strategic focus to critical minerals mining following a recent acquisition, despite reporting significantly increased net losses and substantial doubt about its ability to continue as a going concern for 2025.

Summary

• Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., has undergone a significant strategic pivot, transitioning from a biotechnology company focused on gene therapy and biosimilars to include the development and mining of critical and precious minerals.
• This strategic shift was formalized with the acquisition of Greenland Mines Corp. in March 2026, expanding operations into mining.
• Financially, the company reported a net loss of $10,551,674 for the year ended December 31, 2025, a substantial increase from the $6,150,372 net loss in 2024.
• Operating expenses rose to $7,146,265 in 2025 from $5,540,236 in 2024, driven by increases in general and administrative expenses, research and development, and professional fees.
• The company has incurred recurring losses and negative cash flows from operations, leading to substantial doubt about its ability to continue as a going concern.
• Cash and cash equivalents significantly increased to $7,176,615 as of December 31, 2025, up from $63,741 in 2024, primarily due to $13,002,128 in financing activities, including proceeds from stock and warrant sales and convertible promissory notes.
• The company faces a NASDAQ delisting risk due to its common stock failing to maintain a minimum bid price of $1, though it has received an extension until September 14, 2026, to regain compliance.
• A private placement in March 2026 raised approximately $7,750,000 through the issuance of common stock and warrants.
• The company issued a Senior Convertible Note on January 23, 2025, with an original principal amount of $1,086,957, bearing 7% interest (15% default rate), and convertible into common stock at $0.25 per share.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly concerning filing due to the significant increase in net losses, persistent negative operating cash flow, and the explicit 'going concern' warning. While the pivot to mining and recent capital raise provide some liquidity, the underlying biotech assets are very early stage and the NASDAQ delisting risk remains a critical near-term threat, indicating severe operational and financial challenges.

Positives

• Successfully completed the acquisition of Greenland Mines Corp. in March 2026, diversifying into critical and precious minerals mining.
• Significantly increased cash and cash equivalents to $7,176,615 as of December 31, 2025, up from $63,741 in 2024.
• Improved working capital to $7,216,922 in 2025 from a deficit of $(1,089,723) in 2024.
• Secured $7,750,000 in gross proceeds from a private placement in March 2026.
• Received a six-month extension from Nasdaq until September 14, 2026, to regain compliance with the minimum bid price rule.
• Stockholders approved a reverse stock split and an increase in shares for the 2024 Equity Incentive Plan, providing flexibility for future capital management and employee incentives.
• Holds exclusive, worldwide licenses for gene therapy and biosimilar platforms with issued patents in the U.S., Europe, and China, and pending applications in other major markets.
• Has a sponsored research agreement with UAB with a two-year budget of 623,100 euros to advance gene therapy programs.

Negatives

• Reported a substantial increase in net loss to $10,551,674 for the year ended December 31, 2025, from $6,150,372 in 2024.
• Experienced recurring negative cash flows from operating activities, increasing to $5,889,254 in 2025 from $2,946,512 in 2024.
• The company's financial statements include a "going concern" explanatory paragraph, indicating substantial doubt about its ability to continue operations without additional funding.
• Faces a significant risk of delisting from Nasdaq if it fails to regain compliance with the $1 minimum bid price rule by September 14, 2026.
• Has not generated any operating revenues to date, remaining in a pre-revenue stage.
• Accumulated deficit grew to $21,114,473 as of December 31, 2025.
• Relies heavily on third parties for manufacturing, clinical trials, and commercialization, which introduces execution risks.
• The gene therapy product candidates are in early pre-clinical stages, with significant time and cost required for development and regulatory approval.

Risks

• Incurred significant losses since inception and expects to incur losses for the foreseeable future, potentially never achieving profitability.
• Requires substantial additional funding to meet financial obligations and pursue business objectives, with current cash insufficient to complete all necessary development and commercialization activities.
• Highly dependent on collaborations with Universitat Autnoma de Barcelona (UAB) for preclinical research and development programs.
• Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may adversely impact product development or commercial success.
• Faces significant competition in biosimilar biologics and gene therapy from larger, more experienced biotechnology and pharmaceutical companies.
• May need to license property rights for AAV and lentiviral vectors used in gene therapies.
• Dependent on the success of biosimilar and gene therapy product candidates, which are still in early stages of development with no approved commercial products.
• The evolving regulatory approval processes are lengthy, time-consuming, rigorous, and inherently unpredictable, with no guarantee of approval.
• Results of previous clinical trials may not be predictive of future results, and future trials may not satisfy regulatory requirements.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval or limit commercialization.
• If other biosimilars are deemed interchangeable and the company's are not, business could suffer.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Approved products will remain subject to ongoing regulatory scrutiny and potential sanctions for non-compliance.
• Competition from improved versions of reference products or market decline could impact biosimilar sales.
• Lacks a marketing and sales organization, requiring significant investment or partnerships for commercialization.
• Reliance on third parties (CROs, CDMOs) for manufacturing, quality control, and clinical trials introduces risks of non-compliance or supply issues.
• Gene therapy is a new technology, making development time and cost difficult to predict, and requires development of new in vitro assays for Klotho isoforms.
• Regulatory requirements for gene therapy products change frequently, potentially lengthening the approval process or increasing costs.
• Even if approved, products may fail to achieve market acceptance by physicians, patients, or payors.
• Increasing demand for compassionate use or expanded access to unapproved therapies could negatively affect reputation and divert resources.
• Operations in various international jurisdictions expose the company to business, regulatory, political, operational, financial, and economic risks.
• Subject to stringent and changing privacy and data security laws, with potential for fines, liability, and disruption from security breaches.
• No assurance of reaching and servicing customers profitably as a new business.
• Future issuance of shares could cause dilution of ownership and potential loss of control by present management and stockholders.
• Elimination of personal liability for directors and officers under Delaware law and indemnification rights may result in substantial expenses.
• Significant corporate transactions (acquisitions/dispositions) may not achieve intended results, adversely affect financial condition, or result in unforeseeable risks.
• Reliance on JOBS Act exemptions may make common stock less attractive to investors.
• No dividends are planned in the near future.
• Large sales of common shares by existing stockholders could decline the market price.
• Failure to comply with Nasdaq listing requirements (specifically the $1 minimum bid price rule) could lead to delisting.

Future Outlook

The company plans to complete the animal toxicology package for its KLTO-202 gene therapy candidate and submit an Investigational New Drug (IND) application to the FDA in 2025 for a Phase I Compassionate Use study in late-stage ALS patients. The pre-clinical development for KLTO-101 (Alzheimer's) is expected to follow KLTO-202 by six to nine months, with a corporate partner sought for this indication. The company will also continue to build its platform of next-generation gene and cell delivery technologies and explore opportunities to acquire or license new product candidates. Following the recent acquisition of Greenland Mines Corp., the company is now focused on the development and mining of critical and precious minerals, representing a significant strategic pivot and future growth area. The company expects net cash used in operating activities to increase until products generate meaningful revenue and is dependent on obtaining additional funding to continue operations.

Management Comments

• Management believes that the assumptions and expectations reflected in forward-looking statements are reasonable, based on information available on the date of the report.
• Management expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future as we continue to develop our gene therapy product candidates and prepare for potential future regulatory approvals and commercialization of our products.
• Management believes that despite our material weaknesses [in internal controls], our financial statements for the quarter ended December 31, 2025 are fairly stated, in all material respects, in accordance with GAAP.
• The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations.

Industry Context

StockSavvy.ai notes that Greenland Mines Ltd's strategic pivot into critical and precious minerals mining is a significant departure from its original biotechnology focus. While the biotech sector, particularly gene therapy for neurodegenerative diseases like Alzheimer's and ALS, offers high potential rewards, it is also characterized by extremely long development timelines, high costs, intense competition from well-established pharmaceutical giants (e.g., Biogen, Eli Lilly, Roche), and significant regulatory hurdles. The company's biosimilar efforts also face stiff competition and price erosion. The move into mining could be an attempt to diversify revenue streams and potentially access a more immediate path to commercialization, given the global demand for critical minerals. However, this also introduces a new set of operational, environmental, and market risks distinct from its prior biotech endeavors. The company's financial position, marked by recurring losses and a going concern warning, highlights the challenges of early-stage biotech development and the potential need for a more stable, revenue-generating business.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against for a detailed assessment of industry standards.
• StockSavvy.ai notes that the company's gene therapy candidates (KLTO-101 for Alzheimer's, KLTO-202 for ALS) are in pre-clinical stages, which is typical for novel gene therapies, but places them far behind clinical-stage competitors like Biogen and Eli Lilly in Alzheimer's, or Biogen and Amylyx in ALS, some of whom have already faced market failures (e.g., aducanumab, Relyvrio).
• In the biosimilar market, the company's rituximab and bevacizumab candidates are still in preparatory activities for Phase 3, while competitors like Amgen, Pfizer, Mylan, and Celltrion already have approved and marketed biosimilars, indicating a significant lag and intense market entry challenges.
• The acquisition of mining assets represents a diversification strategy, but without specific operational or financial data for the mining segment, a comparison to established mining industry standards is not yet possible.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings are pending or threatened against the company or its subsidiaries that would have a Material Adverse Effect, other than those required to be described in SEC Documents and not so described.

Related Party Transactions

• The CEO provides office space in Omaha, NE, rent-free to the company.
• Promissory notes were issued to members of management in December 2023 ($135,000, paid by Dec 31, 2024), May 2024 and December 2023 ($7,000 and $24,000, paid by Dec 31, 2025), August 2024 ($80,000, paid by Dec 31, 2024), August 2024 ($20,000, paid by Dec 31, 2025), and September 2024 ($20,000, paid by Dec 31, 2024). All related party notes payable were settled by December 31, 2025.
• Employment agreements with Dr. Joseph Sinkule (CEO) and Jeffrey LeBlanc (CFO) include annual base salaries of $360,000 and $325,000, respectively, and equity awards.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future capital raises and potential loss of investment due to recurring losses and the "going concern" warning. Also, face the risk of NASDAQ delisting, which could severely impact liquidity and share price.
• Employees: The company's ability to attract and retain key personnel, especially in a competitive biotech and now mining market, is crucial for its development objectives. The small size of the accounting staff indicates potential workload and control issues.
• Customers/Patients (Biotech): Potential future beneficiaries of gene therapies for neurodegenerative diseases and biosimilars for cancer, but product development is early-stage and highly uncertain.
• Suppliers/Creditors: Face risks due to the company's "going concern" status and recurring losses, although recent financing has improved short-term liquidity.
• Regulatory Authorities: The company's operations are subject to extensive and evolving regulations, particularly in gene therapy and biosimilars, requiring significant compliance efforts and costs.

Next Steps

• Complete animal toxicology package for KLTO-202.
• Submit Investigational New Drug (IND) application to the FDA in 2025 for a Phase I Compassionate Use study of KLTO-202 in late-stage ALS patients.
• Advance pre-clinical development program for KLTO-101 (Alzheimer's), following KLTO-202 by six to nine months.
• Seek a corporate partner for the development of KLTO-101.
• Develop and validate a new assay method to separate and individually measure Klotho protein isoforms and metabolites.
• Regain compliance with Nasdaq's minimum bid price rule by September 14, 2026, potentially through a reverse stock split.
• Continue to explore opportunities to acquire or license new product candidates and build next-generation gene and cell delivery technologies.

Key Dates

Recommendation

Greenland Mines Ltd presents a highly speculative investment profile. The company's core biotechnology assets are in very early pre-clinical stages, requiring substantial, uncertain, and long-term investment without any current revenue generation. The financial statements explicitly highlight 'substantial doubt about the Company's ability to continue as a going concern' due to recurring losses and negative operating cash flows. Furthermore, the company faces an imminent NASDAQ delisting threat, with an extension only until September 14, 2026, which could severely impair liquidity and investor confidence. While the recent pivot into critical minerals mining and a capital raise provide some short-term liquidity, this new venture is unproven and introduces a new set of risks. The combination of severe financial distress, significant regulatory and development risks in biotech, and the immediate delisting threat makes this a 'strong sell' for any seasoned investor or institution.

Keywords

Mining, Critical Minerals, Precious Minerals, Gene Therapy, Neurodegenerative Diseases, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Klotho, Biosimilars, Oncology, Pharmaceuticals, Biotechnology, SEC Filing, NASDAQ, Convertible Debt, Capital Raise, Corporate Governance, Risk Management